It was reported that bisecting N-GlcNAc modification on EGFR and small extracellular vesicles can diminish malignancy of breast cancer cells, which may contribute to the development of novel targets in breast cancer therapy [16,17]. The gene discussed is EGFR; the disease is breast cancer.